Related references
Note: Only part of the references are listed.Multiple myeloma: 2020 update on diagnosis, risk-stratification and management
S. Vincent Rajkumar
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Hepatitis B virus reactivation in a myeloma patient with resolved infection who received daratumumab-containing salvage chemotherapy
Takaki Kikuchi et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY (2020)
Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B
Hae Lim Lee et al.
DIGESTIVE DISEASES AND SCIENCES (2019)
KASL clinical practice guidelines for management of chronic hepatitis B
Hyung Joon Yim et al.
CLINICAL AND MOLECULAR HEPATOLOGY (2019)
Unmet need in chronic hepatitis B management
Lilian Yan Liang et al.
CLINICAL AND MOLECULAR HEPATOLOGY (2019)
Daratumumab for the Treatment of Multiple Myeloma
Torben Plesner et al.
FRONTIERS IN IMMUNOLOGY (2018)
Humoral immunity, the underestimated player in hepatitis B
Shuye Zhang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
CD38 antibodies in multiple myeloma: back to the future
Niels W. C. J. van de Donk et al.
BLOOD (2018)
Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions
Rohit Loomba et al.
GASTROENTEROLOGY (2017)
Role of Surface Antibody in Hepatitis B Reactivation in Patients With Resolved Infection and Hematologic Malignancy: A Meta-analysis
Sonali Paul et al.
HEPATOLOGY (2017)
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik et al.
BLOOD (2016)
Human CD38: a (r)evolutionary story of enzymes and receptors
S Deaglio et al.
LEUKEMIA RESEARCH (2001)
Share Paper
